Skip to main content
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2012 Jun 5;3:140. doi: 10.3389/fphys.2012.00140

NOX4-Dependent Hydrogen Peroxide Overproduction in Human Atrial Fibrillation and HL-1 Atrial Cells: Relationship to Hypertension

Jun Zhang 1,2, Ji Youn Youn 1,2, Antony Y Kim 3, Rafael J Ramirez 1,2, Ling Gao 1,2, Doan Ngo 1,2, Peng Chen 1,2, Jennifer Scovotti 1,2, Aman Mahajan 1,2, Hua Cai 1,2,*
PMCID: PMC3367314  PMID: 22679437

Abstract

Background/Objectives: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia with patients dying frequently of stroke. In view of the unclear etiologies of AF and a potential role of oxidative stress, the present study examined cardiac reactive oxygen species production and NADPH oxidase (NOX) expression in AF patients. Methods and Results: Patients with AF were older than those without (58.8 ± 11.7 vs. 47.8 ± 19.2, p = 0.047). Whereas total O2- production (determined by electron spin resonance) was similar in patients with and without AF, H2O2 production was more than doubled in AF patients (149.8 ± 26.28 vs. 66.9 ± 7.14 pmol/mg/min, p = 0.0055), which correlated well with a doubling in NOX isoform 4 (NOX4) expression. AF patients with co-existing hypertension had three-fold higher H2O2 production compared to those without (239.0 ± 125.1 vs. 83.6 ± 51.3 pmol/mg/min, p = 0.003). Treatment of HL-1 atrial cells with angiotensin II, a known modulator of atrial structural remodeling, resulted in upregulation of NOX4 and H2O2 production, further implicating a potential role of NOX4 in atrial remodeling. Conclusion: Our data represent the first implication that NOX4-derived H2O2 may play an important role in the etiologies of AF.

Keywords: atrial fibrillation, hydrogen peroxide, NADPH oxidase, NOX4, hypertension, HL-1 cells, angiotensin II

Introduction

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia that is rapidly developing into an epidemic (Savelieva and Camm, 2008). It is associated with markedly increased risk of stroke, due to dislocation of thrombi that are most often originated from left atrial appendage (LAA). Although AF is clearly associated with aging, and cardiovascular conditions such as hypertension, mitral valve stenosis, and heart failure, molecular mechanisms underlying its etiology have remained elusive. Recent advances seem to suggest that AF is initiated by atrial structural and electrical remodeling, and that AF itself further augments these responses to perpetuate AF (Savelieva and Camm, 2008; Chou and Chen, 2009).

The known risk factors for AF have all been linked to oxidative stress, and inflammatory factors such as angiotensin II (Ang II) (Kannel et al., 1998; Nakashima et al., 2000; Kim et al., 2003, 2005). Ang II is a major vasoconstrictive hormone and its production is elevated in patients with hypertension. It is also involved in modulating cardiac hypertrophy and remodeling. Of note, hypertension is considered the most prevalent risk factor for AF. Atrial structural remodeling can be induced by Ang II, resulting in atrial fibrosis and possibly initiation of AF (Zografos and Katritsis, 2010; Tan and Zimetbaum, 2011). A meta-analysis of 7 clinical trials involving a total of 24,849 patients receiving ACEIs and/or ARBs for treatment of hypertension, ischemic heart disease, heart failure, or diabetes mellitus demonstrated that ACEIs/ARBs significantly reduces the risk of AF or its recurrence by 28% (Healey et al., 2005). Importantly, Ang II is an extremely potent activator of NADPH oxidase (NOX) in the vascular cells (Cai et al., 2003; Choi et al., 2008; Lassegue and Griendling, 2010). NOX-dependent reactive oxygen species (ROS) production leads to nitric oxide (NO) inactivation and endothelial dysfunction, which underlie pathogenesis of vascular diseases such as hypertension and atherosclerosis (Cai and Harrison, 2000; Cai et al., 2003; Cai, 2005a,b). We hypothesize that NOX-derived ROS might be important in mediating Ang II-dependent development of AF. Some interesting data exist to show that hydrogen peroxide increases Kv1.5 current amplitude at voltages corresponding to the action potential repolarization phase and accelerate Kv1.5 channel opening. These changes can reduce the action potential duration, leading to a shortening of the atrial effective refractory period (Caouette et al., 2003)

To test this hypothesis in human AF, cardiac tissues from heart transplant patients were examined for ROS production and expression of NOX isoforms. Interestingly, we found a specific upregulation of NOX4 that was correlated with H2O2 overproduction in AF patients. None of the other NOX isoforms were however regulated in AF. AF patients with co-existing hypertension had more than 3-fold increase in H2O2 production compared to those without. In atrial HL-1 cells, Ang II treatment led to increased AT1 receptor expression, upregulation of NOX4 and increased H2O2 production. These human and cell culture data together implicate that there might be a novel role of NOX4-derived H2O2 in mediating Ang II-dependent AF development.

Materials and Methods

Patient population

Left atrial appendage tissues isolated from randomly recruited patients undergoing cardiac transplant surgeries were subjected to electron spin resonance (ESR) determination of O2- production, Amplex red determination of H2O2 production and RT-PCR analysis of NOX gene expression. The study was carried out in a double-blinded fashion. Clinical information was gathered upon completion of laboratory analyses. IRB approval was obtained for these studies.

Electron spin resonance detection of superoxide radical

The specific O2- spin trap CMH (0.5 mmol/L; Noxygen) solution was prepared freshly in nitrogen gas bubbled Krebs/HEPES buffer containing diethyldithiocarbamic acid (DETC; 5 μmol/l; Sigma) and deferoxamine (25 μmol/l; Sigma). The LAA homogenates (in 50 mmol/L Tris–HCl, pH 7.4, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, and 1% (v/v) of protease inhibitor cocktail from Sigma) were then mixed with the spin trap solution and loaded into glass capillary (Fisher Scientific) for analysis of O2- production using ESR spectrometer (Bruker), following a similar procedure as we previously published for cultured endothelial cells (Chalupsky and Cai, 2005; Gao et al., 2009a,b) intact mouse aortas (Chalupsky and Cai, 2005; Oak and Cai, 2007; Gao et al., 2009a), and tissue homogenates (Lu et al., 2009). The ESR settings used were as follows: bio-field 3,410, field sweep 100G, microwave frequency 9.73 GHz, microwave power 13.26 mW, modulation amplitude 9.82G and 512 points of resolution.

Amplex-red assay of hydrogen peroxide production

The LAA lysates [in 20 mmol/L Tris–HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L EDTA, 1% (v/v) Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L Na3VO4, 1 mmol/L β-glycerolphosphate, 1 mmol/L PMSF, 1% (v/v) of protease inhibitor cocktail from Sigma] were analyzed for H2O2 production using a fluorometric horseradish peroxidase assay (Amplex-Red assay; Molecular Probes). Fluorescence was measured (excitation 530 nm and emission 590 nm) after 1 h of incubation at 37°C in the dark against background fluorescence of buffer. Polyethylene glycol-conjugated catalase (500 U/ml, Sigma) inhibitable fraction reflects specific H2O2 signal. The rate of H2O2 production was presented as picomoles per milligram protein per minute after calculation, according to a standard curve generated using fresh H2O2 in reaction buffer.

RT-PCR analysis of NOX mRNA expression

Total RNA was extracted from the LAA using TRIzol (Invitrogen) according to the manufacturer’s instructions. Reverse transcription was performed in standard fashion with iScript cDNA synthesis Kit (Bio-Rad). The primer sequences used for PCR reactions are summarized in Table 1. The PCRs were carried out using an iCycler (Bio-Rad) with the protocol of [(95°C/2 min) (95°C/25 s, 57°C/5 s, 68°C 5 min) × 35 (72°C/10 min)]. The PCR mix contained GAPDH primers to generate GAPDH amplicon that served as an internal control.

Table 1.

Primer sequences for RT-PCR.

Gene Sequence (5′→3′)
NOX1 Forward CAATCTCTCTCCTGGAATGGCATCCT
Reverse CCTGCTGCTCGGATATGAATGGAGAA
NOX2 Forward AAGGCTTCAGGTCCACAGAGGAAA
Reverse AGACTTTGTATGGACGGCCCAACT
NOX3 Forward ACCGTGGAGGAGGCAATTAGACAA
Reverse CAGGTTGAAGAAATGCGCCACGAT
NOX4 Forward AGCAGAGCCTCAGCATCTGTTCTT
Reverse TGGTTCTCCTGCTTGGAACCTTCT
NOX5 Forward CCTCCTCATGTTCATCTGCTCCAGTT
Reverse AGGAGGTAGGACAGGTGAGTCCAATA

HL-1 cell culture and stimulation by Ang II

The HL-1 cells were obtained as generous gifts from Dr. William Claycomb from Louisiana State University that have been extensively characterized to maintain its differentiated cardiac phenotype using microscopic, genetic, immunohistochemical, electrophysiological, and pharmacological techniques (Claycomb et al., 1998; White et al., 2004). These beating cells were cultured following exact protocols as established by the Claycomb group and found to keep their phenotype during the 24 h exposure period to Ang II. The confluent cells were kept quiescent in media containing 0.01% FBS overnight and then stimulated with Ang II (100 nmol/L) for 24 h prior to analysis of NOX4 protein expression by Western blot (primary antibody from Abcam) and H2O2 production by Amplex Red assay. NOX4 mRNA expression from identically treated cells was determined by real-time RT-PCR.

Statistical analysis

All data are presented as mean ± SEM. Differences in O2- production, H2O2 production, and mRNA expression of different NOX isoforms between AF and non-AF groups were compared using t tests. ANCOVA were performed to examine the correlation between H2O2 and NOX4 mRNA expression in patients with and without AF. Statistical significance was set as p < 0.05.

Results

Patient characteristics

Patient characteristics are summarized in Table 2. Eighteen patients with AF were older than those without (n = 17; p = 0.047). The gender distribution was not different. Both groups had similar incidence of co-existing cardiovascular conditions including hypertension, diabetes, and coronary artery disease. The percentages of patients receiving treatment of ACEI, AT1RB, calcium blocker or beta blocker were also similar between the two groups (Table 2). Of note, there was no significant difference in ejection fraction between the AF and non-AF groups. Whereas diastolic blood pressure, total cholesterol and triglyceride levels were not different in the AF vs. non-AF groups, systolic blood pressure (SBP) was higher in the AF patients (Table 2). ACEI-treated AF group had modestly higher SBP than those of non-AF group receiving ACEI (Table 3).

Table 2.

Patient characteristics.

Characteristic Non-AF AF p Value
Age 47.8 ± 19.2 58.8 ± 11.7 0.047
Gender (%male) 70% 61% 0.568
Hypertension 59% 39% 0.251
Diabetes 29% 28% 0.917
CAD 41% 33% 0.643
Family history of heart disease 65% 44% 0.409
ACEI Therapy 53% 44% 0.627
AT1RB Therapy 29% 17% 0.384
Ca++ blocker therapy 0% 11% 0.166
Beta blocker therapy 76% 55% 0.203
SBP (mmHg) 107.1 ± 18.3 120.8 ± 13.9 0.033
DBP (mmHg) 66.6 ± 12.2 73.8 ± 8.3 0.074
Ejection fraction (% by ECHO) 20.82 ± 2.3 22.67 ± 2.5 0.586
TC (mg/dL) 158.6 ± 33.6 158.0 ± 44.1 0.967
TG (mg/dL) 137.8 ± 57.2 144.5 ± 53.6 0.266

CAD, coronary artery disease; ACEI, angiotensin converting enzyme inhibitor; AT1RB, angiotensin II type-1 (AT1) receptor blocker; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides.

Table 3.

Blood pressure control in patient subgroups.

Characteristic ACEI
Non-ACEI
Non-AF (n = 7) AF (n = 8) p Value Non-AF (n = 8) AF (n = 12) p Value
SBP 104.1 ± 16.2 119.1 ± 12.4 0.024 110.6 ± 19.4 123 ± 16.8 0.236
DBP 68.6 ± 11.0 74.5 ± 9.4 0.236 70.2 ± 10.3 76.4 ± 4.4 0.233

AT1RB
Non-AT1RB
Non-AF (n = 12) AF (n = 4) p Value Non-AF (n = 13) AF (n = 6) p Value

SBP 120.8 ± 16.6 131 ± 26.9 0.530 101.7 ± 14.3 119.1 ± 11.9 0.003
DBP 75.1 ± 5.2 78.5 ± 3.5 0.444 67.8 ± 11.4 74.3 ± 7.9 0.120

Reactive oxygen species production

Among biologically relevant and abundant ROS, O2-, and H2O2 appear to be most important in redox signaling. Whereas O2- predominantly induces endothelial dysfunction by rapidly inactivating nitric oxide (NO), H2O2 influences different aspects of endothelial cell function via complex mechanisms. We hypothesize that O2- and H2O2 also have differential roles in the regulation of cardiac functions. Both species were quantitatively and specifically determined by ESR and Amplex Red assay respectively. Whereas total O2- production was not different between AF and non-AF groups (Figure 1A), we found that H2O2 production was more than doubled in AF patients compared to those without (149.8 ± 26.28 vs. 66.9 ± 7.14 pmol/mg/min, p = 0.0055, Figure 1B).

Figure 1.

Figure 1

Superoxide and hydrogen peroxide production in patients with and without atrial fibrillation. (A) Total superoxide production. LAA were homogenated and subsequently analyzed for superoxide production using ESR. (B) Hydrogen peroxide production. LAA lysates were analyzed for hydrogen peroxide production using the Amplex Red assay.

H2O2 production in AF patients with co-existing hypertension

Interestingly, AF patients with co-existing hypertension had approximately 3-fold higher H2O2 production compared to those without (239.0 ± 125.1 vs. 83.6 ± 51.3 pmol/mg/min, p = 0.003, Table 4). Older AF patients (>50) also had higher tissue levels of H2O2 compared to those younger AF patients (<50; 165 ± 118.8 vs. 95.0 ± 64.9 pmol/mg/min), although yet reaching statistical significance. In contrast, hypertension or age had no effect on H2O2 levels in patients without AF (Table 4).

Table 4.

Hydrogen peroxide levels in patient subgroups.

Characteristic Non-AF
AF
Absence Presence p Value Absence Presence P Value
Hypertension 58.1 ± 25.7 (n = 6) 71.7 ± 31.4 (n = 11) 0.379 83.6 ± 51.3 (n = 11) 239.0 ± 125.1 (n = 7) 0.003
Diabetes 77.4 ± 33.7 (n = 12) 51.8 ± 12.5 (n = 5) 0.076 151.8 ± 122.7 (n = 13) 144.8 ± 87.3 (n = 5) 0.909
CAD 55.6 ± 13.9 (n = 10) 71.6 ± 33.3 (n = 7) 0.321 155.0 ± 123.8 (n = 12) 139.4 ± 91.6 (n = 6) 0.789
Gender Male Female Male Female
65.9 ± 32.2 (n = 13) 69.8 ± 21.6 (n = 4) 0.828 136.6 ± 117.9 (n = 11) 170.6 ± 105.9 (n = 7) 0.544
Age <50
53.3 ± 14.6 (n = 8)
>50
79.0 ± 34.5 (n = 9)
0.070 <50
95.0 ± 64.9 (n = 4)
>50
165.5 ± 118.8 (n = 14)
0.278

Expression of different NOX isoforms and its relationship to H2O2

NOX4 is known to either produce H2O2 directly, or produce O2- in subcellular organelles leaving membrane permeable H2O2 the sole detectable species (Martyn et al., 2006; Lambeth et al., 2007; Serrander et al., 2007; Chen et al., 2008; Block et al., 2009; Lassegue and Griendling, 2010). Other NOX isoforms however, have been shown to produce O2- directly (Choi et al., 2008). Intriguingly, NOX4 mRNA expression was found significantly upregulated in AF patients (Figure 2A), which correlated well with a marked increase in H2O2 production (Figure 2B). The expression of NOX1 and NOX2 however, was not different in patients with and without AF (Figures 3A,B). NOX3 and NOX5 were not detectable in LAA. We did not find any correlation between ejection fractions and NOX4/H2O2 levels in both groups. This indicates that severity of heart failure is not linked to NOX4-H2O2 axis as AF does.

Figure 2.

Figure 2

Upregulation of NOX4 expression and its correlation with hydrogen peroxide production in patients with atrial fibrillation. (A) NOX4 mRNA expression. NOX4 mRNA expression was determined by RT-PCR analysis and normalization to endogenous amplicon of GAPDH. (B) Correlation between NOX4 mRNA expression and hydrogen peroxide production.

Figure 3.

Figure 3

Expression of different NOX isoforms in patients with and without atrial fibrillation. (A) NOX1 mRNA expression. (B) NOX2 mRNA expression. NOX1 or NOX2 mRNA expression was determined by RT-PCR analysis and normalization to endogenous amplicon of GAPDH.

NOX4 expression and H2O2 production in Ang II-stimulated HL-1 atrial cells

In additional experiments, we examined whether Ang II activates NOX4 in HL-1 atrial cells that have been well characterized to maintain a differentiated, adult cardiomyocyte and atrial cell-like phenotype. In our hand we have also been able to reproduce the culture condition and observe the beating HL-1 cells following the published Claycomb conditions. Of note, the Ang II receptor AT1 was abundantly expressed in these cells, and it was upregulated by Ang II (Figures 4A,C). Ang II stimulation resulted in upregulation of NOX4 protein expression and an associated increase in H2O2 production (Figures 4A,B,D). The NOX4 mRNA expression, determined by real-time RT-PCR, was also found upregulated by Ang II in HL-1 cells (Figure 4E).

Figure 4.

Figure 4

NOX4, AT1R expression and hydrogen peroxide production in angiotensin II treated HL-1 atrial cells. (A) Representative Western blots of NOX4 and AT1R expression in Ang II treated HL-1 cells. (B) Densitometic grouped data of NOX4 expression in Ang II treated HL-1 cells. (C) Densitometic grouped data of NOX4 expression in Ang II treated HL-1 cells. (D) Hydrogen peroxide production in Ang II treated HL-1 cells. (E) NOX4 mRNA expression in Ang II treated HL-1 cells. Data are represented as Mean ± SEM (N = 4, *p < 0.05 vs. CTRL).

Discussion

In the present study, we have discovered that NOX4-derived H2O2 production is markedly increased in the LAA tissues of AF patients. Hydrogen peroxide production in LAA was 3-fold higher in AF patients with co-existing hypertension than those without. Hypertension is an established risk factor for AF. Recent studies have indicated that H2O2 regulates electrical properties of isolated rabbit pulmonary vein and atrial cells (Lin et al., 2010). Together with the previously characterized role of H2O2 in myocardial fibrosis, these data suggest that NOX4-derived H2O2 may play an important role in the development of AF. Indeed, in additional studies utilizing HL-1 atrial cells, we found that Ang II stimulation led to NOX4 upregulation and increased H2O2 production, further implicating a potential role of NOX4-derived H2O2 in atrial structural remodeling that is considered an important initiating process of AF.

Aging and hypertension are the best-characterized, potential causal factors for AF. Of significant interest, we found that AF patients with co-existing hypertension had 3-folds higher H2O2 production compared to those without AF. AF patients that are older (>50) also had apparently higher H2O2 production. These observations may further suggest that augmented local cardiac production of H2O2 is involved in arrhythmogenesis, besides its proinflammatory and prothrombotic effects. On the other hand, AF may have made SBP control more difficult (ACEI-AF group had higher SBP than ACEI-non-AF group), which is likely related to the substantially higher H2O2 production in hypertensive AF patients. Although H2O2 can mediate compensatory relaxation under certain conditions such as in the apolipoprotein E deficient atherosclerotic mice (Landmesser et al., 2003), excessive H2O2 is involved in vascular remodeling which could in turn result in stiffer blood vessels to deteriorate hypertension.

We found that LAA O2- production was not different in patients with and without AF. We also found that xanthine oxidase derived O2- was not different between the two groups (data not shown). Xanthine oxidase has been previously shown to play an important role in cardiac O2- production in patients with heart failure. However its role in AF patients has never been previously tested. It is interesting to speculate whereas xanthine oxidase and/or other NOX isoforms is more important for O2- production in heart failure patients, NOX4-derived H2O2 production is more important in the condition of AF. Of course, this hypothesis needs to be further investigated using larger patient population. Potential regulations of ROS scavenging enzymes such as superoxide dismutases and glutathione peroxidases, under the environment of NOX4-dependent H2O2 overproduction, would also be interesting to be further investigated.

Our data revealed an innovative role of NOX4 in H2O2 production in AF patients. Previously NOX1 and NOX4 were found undetectable in RAA (Kim et al., 2005). In human LAA, however, we were able to detect abundant NOX1, NOX2, and NOX4 mRNA expression. Only NOX4 mRNA expression was upregulated by AF, which correlated well with overproduction of H2O2 in AF patients. Accumulating evidence have characterized the relatively newly recognized NOX4 and its ROS-producing activity in various cell types such as endothelial cells (Ago et al., 2004, 2005), vascular smooth muscle (Lassegue et al., 2001; Wingler et al., 2001; Touyz et al., 2002), and kidney cells (Shiose et al., 2001; Wingler et al., 2001; Chabrashvili et al., 2002). Functionally, NOX4 has been implicated in cell differentiation (Clempus et al., 2007; Ismail et al., 2009; Schroder et al., 2009; Xiao et al., 2009), cell cycle transition (Sturrock et al., 2007), transcriptional activation (Bonello et al., 2007), and myofibroblast activation and fibrogenic responses (Hecker et al., 2009). In the heart, NOX4 has been shown to be involved in hypertrophy induced cardiac apoptosis and mitochondrial dysfunction (Ago et al., 2010), and pressure overload-induced heart failure (Byrne et al., 2003; Kuroda et al., 2010). Our data add to this rapidly growing knowledge of NOX4 functions, demonstrating a potential role of NOX4 in enhancing H2O2 production in patients with AF, which might be involved in the pathogenesis of AF. Of note, recent studies have demonstrated an important role of myocardial fibrosis in AF (Everett and Olgin, 2007). Therefore, H2O2 may also contribute to AF via augmentation of myocardial fibrosis as recently reported (Morita et al., 2009).

HL-1 cardiomyocytes, derived from atrial cardiac muscle cells from the AT1 mouse atrial cardiomyocyte tumor lineage, maintains the differentiated adult cardiomyocyte phenotype (Claycomb et al., 1998). This cell has been proved to possess the organized sarcomere, ion channels, functional receptors, and intracellular signaling proteins so that it contracts spontaneously, divides, generates action potential, and responds to agonists (White et al., 2004). Therefore, HL-1 cardiomyocyte has been established as the useful tool to study the cellular and molecular mechanisms underlying cardiac pathophysiologies (Rodriguez-Sinovas et al., 2005; Brady et al., 2006; Barba et al., 2009). In particular, expression of renin–angiotensin system components and Ang II regulation of L-type calcium channel have been characterized in HL-1 cells (Tsai et al., 2007, 2008). Moreover, transcriptional profile regulated by rapid electrical stimulation in HL-1 cells was similar to those from human AF (Mace et al., 2009). Therefore, we employed HL-1 cells as the cellular model to investigate whether NOX4 is modulated by Ang II, which has been shown to modulate atrial remodeling and fibrillation. We found AT1R was expressed in HL-1 cells and further upregulated by Ang II treatment. Most importantly, exposure of HL-1 cells to Ang II resulted in increased NOX4 mRNA and protein expression, without affecting NOX1 and NOX2 mRNA levels. This was accompanied by a significant elevation in H2O2 production.

In summary, our data have uncovered a NOX4-mediated overproduction of H2O2 in patients with AF. AF patients with hypertension had markedly higher LAA H2O2 levels compared to those without AF. In addition, H2O2 has been recently reported to regulate electrical properties of pulmonary vein and atrial cells, where the initiation of ectopic beats is believed to occur to induce AF. It is also known to promote myocardial fibrosis. The modulator of atrial remodeling and fibrosis, Ang II, also significantly upregulated NOX4 expression and H2O2 production in atrial HL-1 cells. Taken together, these data suggest that NOX4 may play an important role in the pathogenesis of AF.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors’ work has been supported by National Heart, Lung and Blood Institute (NHLBI) Grant HL077440 (Hua Cai), HL081571 (Hua Cai), HL088975 (Hua Cai), HL101228 (Hua Cai, PP Ping, JN Weiss) and HL108701 (Hua Cai, DG Harrison).

References

  1. Ago T., Kitazono T., Kuroda J., Kumai Y., Kamouchi M., Ooboshi H., Wakisaka M., Kawahara T., Rokutan K., Ibayashi S., Iida M. (2005). NAD(P)H oxidases in rat basilar arterial endothelial cells. Stroke 36, 1040–1046 [DOI] [PubMed] [Google Scholar]
  2. Ago T., Kitazono T., Ooboshi H., Iyama T., Han Y. H., Takada J., Wakisaka M., Ibayashi S., Utsumi H., Iida M. (2004) Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109, 227–233 10.1161/01.CIR.0000105680.92873.70 [DOI] [PubMed] [Google Scholar]
  3. Ago T., Kuroda J., Pain J., Fu C., Li H., Sadoshima J. (2010). Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 106, 1253–1264 10.1161/CIRCRESAHA.109.213116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barba I., Chavarria L., Ruiz-Meana M., Mirabet M., Agullo E., Garcia-Dorado D. (2009). Effect of intracellular lipid droplets on cytosolic Ca2+ and cell death during ischaemia-reperfusion injury in cardiomyocytes. J. Physiol. (Lond.) 587, 1331–1341 10.1113/jphysiol.2008.163311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Block K., Gorin Y., Abboud H. E. (2009). Subcellular localization of Nox4 and regulation in diabetes. Proc. Natl. Acad. Sci. U.S.A. 106, 14385–14390 10.1073/pnas.0906805106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bonello S., Zahringer C., BelAiba R. S., Djordjevic T., Hess J., Michiels C., Kietzmann T., Gorlach A. (2007). Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler. Thromb. Vasc. Biol. 27, 755–761 10.1161/01.ATV.0000258979.92828.bc [DOI] [PubMed] [Google Scholar]
  7. Brady N. R., Hamacher-Brady A., Gottlieb R. A. (2006). Proapoptotic BCL-2 family members and mitochondrial dysfunction during ischemia/reperfusion injury, a study employing cardiac HL-1 cells and GFP biosensors. Biochim. Biophys. Acta 1757, 667–678 10.1016/j.bbabio.2006.04.011 [DOI] [PubMed] [Google Scholar]
  8. Byrne J. A., Grieve D. J., Bendall J. K., Li J. M., Gove C., Lambeth J. D., Cave A. C., Shah A. M. (2003). Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ. Res. 93, 802–805 10.1161/01.RES.0000099504.30207.F5 [DOI] [PubMed] [Google Scholar]
  9. Cai H. (2005a). Hydrogen peroxide regulation of endothelial function: mechanisms, consequences and origins. Cardiovasc. Res. 68, 26–36 10.1016/j.cardiores.2005.06.021 [DOI] [PubMed] [Google Scholar]
  10. Cai H. (2005b). NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 96, 818–822 10.1161/01.RES.0000163631.07205.fb [DOI] [PubMed] [Google Scholar]
  11. Cai H., Griendling K. K., Harrison D. G. (2003). The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24, 471–478 10.1016/S0165-6147(03)00233-5 [DOI] [PubMed] [Google Scholar]
  12. Cai H., Harrison D. G. (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840–844 [DOI] [PubMed] [Google Scholar]
  13. Caouette D., Dongmo C., Berube J., Fournier D., Daleau P. (2003). Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch. Pharmacol. 368, 479–486 10.1007/s00210-003-0834-0 [DOI] [PubMed] [Google Scholar]
  14. Chabrashvili T., Tojo A., Onozato M. L., Kitiyakara C., Quinn M. T., Fujita T., Welch W. J., Wilcox C. S. (2002). Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39, 269–274 10.1161/hy0202.103264 [DOI] [PubMed] [Google Scholar]
  15. Chalupsky K., Cai H. (2005). Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 102, 9056–9061 10.1073/pnas.0409594102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chen K., Kirber M. T., Xiao H., Yang Y., Keaney J. F., Jr. (2008). Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 181, 1129–1139 10.1083/jcb.200709049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Choi H., Leto T. L., Hunyady L., Catt K. J., Bae Y. S., Rhee S. G. (2008). Mechanism of angiotensin II-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J. Biol. Chem. 283, 255–267 10.1074/jbc.M803695200 [DOI] [PubMed] [Google Scholar]
  18. Chou C. C., Chen P. S. (2009). New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol. Clin. 27, 35–33 10.1016/j.ccl.2008.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Claycomb W. C., Lanson N. A., Jr., Stallworth B. S., Egeland D. B., Delcarpio J. B., Bahinski A., Izzo N. J., Jr. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U.S.A. 95, 2979–2984 10.1073/pnas.95.6.2979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Clempus R. E., Sorescu D., Dikalova A. E., Pounkova L., Jo P., Sorescu G. P., Schmidt H. H., Lassegue B., Griendling K. K. (2007). Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 27, 42–48 10.1161/01.ATV.0000251500.94478.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Everett T. H., Olgin J. E. (2007). Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4, S24–S27 10.1016/j.hrthm.2007.03.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gao L., Chalupsky K., Stefani E., Cai H. (2009a). Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice. A Novel HPLC-based Fluorescent Assay for DHFR Activity. J. Mol. Cell. Cardiol. 47, 752–760 10.1016/j.yjmcc.2009.07.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gao L., Pung Y. F., Zhang J., Chen P., Wang T., Li M., Meza M., Toro L., Cai H. (2009b). Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. Am. J. Physiol. Heart Circ. Physiol. 297, H331–H339 10.1152/ajpheart.00817.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Healey J. S., Baranchuk A., Crystal E., Morillo C. A., Garfinkle M., Yusuf S., Connolly S. J. (2005). Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45, 1832–1839 10.1016/j.jacc.2004.11.070 [DOI] [PubMed] [Google Scholar]
  25. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T. R., Horowitz J. C., Pennathur S., Martinez F. J., Thannickal V. J. (2009). NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15, 1077–1081 10.1038/nm.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ismail S., Sturrock A., Wu P., Cahill B., Norman K., Huecksteadt T., Sanders K., Kennedy T., Hoidal J. (2009). NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am. J. Physiol. Lung Cell Mol. Physiol. 296, L489–L499 10.1152/ajplung.90488.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kannel W. B., Wolf P. A., Benjamin E. J., Levy D. (1998). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82, 2N–9N 10.1016/S0002-9149(98)00526-8 [DOI] [PubMed] [Google Scholar]
  28. Kim Y. H., Lee J. H., Lim do S., Shim W. J., Ro Y. M., Park G. H., Becker K. G., Cho-Chung Y. S., Kim M. K. (2003). Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp. Mol. Med. 35, 336–349 [DOI] [PubMed] [Google Scholar]
  29. Kim Y. M., Guzik T. J., Zhang Y. H., Zhang M. H., Kattach H., Ratnatunga C., Pillai R., Channon K. M., Casadei B. (2005). A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97, 629–636 10.1161/01.RES.0000183735.09871.61 [DOI] [PubMed] [Google Scholar]
  30. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M. D., Sadoshima J. (2010). NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. U.S.A. 107, 15565–15570 10.1073/pnas.0911647107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lambeth J. D., Kawahara T., Diebold B. (2007). Regulation of Nox and Duox enzymatic activity and expression. Free Radic. Biol. Med. 43, 319–331 10.1016/j.freeradbiomed.2007.03.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Landmesser U., Dikalov S., Price S. R., McCann L., Fukai T., Holland S. M., Mitch W. E., Harrison D. G. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111, 1201–1209 10.1172/JCI200314172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lassegue B., Griendling K. K. (2010). NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 30, 653–661 10.1161/ATVBAHA.108.181610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lassegue B., Sorescu D., Szocs K., Yin Q., Akers M., Zhang Y., Grant S. L., Lambeth J. D., Griendling K. K. (2001). Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ. Res. 88, 888–894 10.1161/hh0901.090299 [DOI] [PubMed] [Google Scholar]
  35. Lin Y. K., Lin F. Z., Chen Y. C., Cheng C. C., Lin C. I., Chen Y. J., Chen S. A. (2010). Oxidative stress on pulmonary vein and left atrium arrhythmogenesis. Circ. J. 74, 1547–1556 10.1253/circj.CJ-09-0999 [DOI] [PubMed] [Google Scholar]
  36. Lu G., Sun H., Korge P., Koehler C. M., Weiss J. N., Wang Y. (2009). Functional characterization of a mitochondrial Ser/Thr protein phosphatase in cell death regulation. Meth. Enzymol. 457, 255–273 10.1016/S0076-6879(09)05014-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Mace L. C., Yermalitskaya L. V., Yi Y., Yang Z., Morgan A. M., Murray K. T. (2009). Transcriptional remodeling of rapidly stimulated HL-1 atrial myocytes exhibits concordance with human atrial fibrillation. J. Mol. Cell. Cardiol. 47, 485–492 10.1016/j.yjmcc.2009.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Martyn K. D., Frederick L. M., von Loehneysen K., Dinauer M. C., Knaus U. G. (2006). Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell. Signal. 18, 69–82 10.1016/j.cellsig.2005.03.023 [DOI] [PubMed] [Google Scholar]
  39. Morita N., Sovari A. A., Xie Y., Fishbein M. C., Mandel W. J., Garfinkel A., Lin S. F., Chen P. S., Xie L. H., Chen F., Qu Z., Weiss J. N., Karagueuzian H. S. (2009). Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 297, H1594–H1605 10.1152/ajpheart.00579.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nakashima H., Kumagai K., Urata H., Gondo N., Ideishi M., Arakawa K. (2000). Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101, 2612–2617 [DOI] [PubMed] [Google Scholar]
  41. Oak J. H., Cai H. (2007). Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 56, 118–126 10.2337/db06-0288 [DOI] [PubMed] [Google Scholar]
  42. Rodriguez-Sinovas A., Garcia-Dorado D., Pina P., Ruiz-Meana M., Soler-Soler J. (2005). Effect of sarcolemmal rupture on myocardial electrical impedance during oxygen deprivation. Am. J. Physiol. Heart Circ. Physiol. 288, H1396–H1403 10.1152/ajpheart.00768.2004 [DOI] [PubMed] [Google Scholar]
  43. Savelieva I., Camm J. (2008). Update on atrial fibrillation: part I. Clin. Cardiol. 31, 55–62 10.1002/clc.20138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Schroder K., Wandzioch K., Helmcke I., Brandes R. P. (2009). Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler. Thromb. Vasc. Biol. 29, 239–245 10.1161/ATVBAHA.108.174219 [DOI] [PubMed] [Google Scholar]
  45. Serrander L., Cartier L., Bedard K., Banfi B., Lardy B., Plastre O., Sienkiewicz A., Forro L., Schlegel W., Krause K. H. (2007). NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem. J. 406, 105–114 10.1042/BJ20061903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Shiose A., Kuroda J., Tsuruya K., Hirai M., Hirakata H., Naito S., Hattori M., Sakaki Y., Sumimoto H. (2001). A novel superoxide-producing NAD(P)H oxidase in kidney. J. Biol. Chem. 276, 1417–1423 10.1074/jbc.M007597200 [DOI] [PubMed] [Google Scholar]
  47. Sturrock A., Huecksteadt T. P., Norman K., Sanders K., Murphy T. M., Chitano P., Wilson K., Hoidal J. R., Kennedy T. P. (2007). Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1543–L1555 10.1152/ajplung.00430.2006 [DOI] [PubMed] [Google Scholar]
  48. Tan A. Y., Zimetbaum P. (2011). Atrial fibrillation and atrial fibrosis. J. Cardiovasc. Pharmacol. 57, 625–629 10.1097/FJC.0b013e3182073c78 [DOI] [PubMed] [Google Scholar]
  49. Touyz R. M., Chen X., Tabet F., Yao G., He G., Quinn M. T., Pagano P. J., Schiffrin E. L. (2002). Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90, 1205–1213 10.1161/01.RES.0000020404.01971.2F [DOI] [PubMed] [Google Scholar]
  50. Tsai C. T., Lai L. P., Hwang J. J., Chen W. P., Chiang F. T., Hsu K. L., Tseng C. D., Tseng Y. Z., Lin J. L. (2008). Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J. Hypertens. 26, 570–582 10.1097/HJH.0b013e3282f34a4a [DOI] [PubMed] [Google Scholar]
  51. Tsai C. T., Wang D. L., Chen W. P., Hwang J. J., Hsieh C. S., Hsu K. L., Tseng C. D., Lai L. P., Tseng Y. Z., Chiang F. T., Lin J. L. (2007). Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes. Circ. Res. 100, 1476–1485 10.1161/01.RES.0000268497.93085.e1 [DOI] [PubMed] [Google Scholar]
  52. White S. M., Constantin P. E., Claycomb W. C. (2004). Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. Heart Circ. Physiol. 286, H823–H829 10.1152/ajpheart.00986.2003 [DOI] [PubMed] [Google Scholar]
  53. Wingler K., Wunsch S., Kreutz R., Rothermund L., Paul M., Schmidt H. H. (2001). Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic. Biol. Med. 31, 1456–1464 10.1016/S0891-5849(01)00727-4 [DOI] [PubMed] [Google Scholar]
  54. Xiao Q., Luo Z., Pepe A. E., Margariti A., Zeng L., Xu Q. (2009). Embryonic stem cell differentiation into smooth muscle cells is mediated by Nox4-produced H2O2. Am. J. Physiol. Cell Physiol. 296, C711–C723 10.1152/ajpcell.00442.2008 [DOI] [PubMed] [Google Scholar]
  55. Zografos T., Katritsis D. G. (2010). Inhibition of the renin-angiotensin system for prevention of atrial fibrillation. Pacing Clin. Electrophysiol. 33, 1270–1285 10.1111/j.1540-8159.2010.02832.x [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES